Effect of oral pilocarpine in severe dry eye syndrome

Effect of oral pilocarpine in severe dry eye syndrome - Effect of oral pilocarpine in severe dry eye syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021268

Enrollment

Registered

2016-03-02

Start date

2012-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eye syndrome

Interventions

Current eye drop + oral pilocarpine (7.5mg 3 times/ day) Current eye drop only.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Dry eye symdorome criteria defined by Japanese dry eye society was used for diagnosis. 1. ocular symptoms 2. tear abnormality (Shirmer test or BUT) 3. corneal epithelial damage: corneal staining score

Exclusion criteria

Exclusion criteria: Patients with following disease are excluded. myocardial infarction/ angina asthma/COPD infarction of digestive tract or cervix of bladder epilepsy Parkinson disease iritis previous allergic reaction to pilocarpine

Design outcomes

Primary

Measure	Time frame
ocular symptoms, fluorescein staining score, rose-bengal staining score, Schirmer test I, tear break up time, and tear clearance test after 1month of oral pilocarpine.	—

Countries

Japan

Contacts

Public ContactTetsuya Kawakita

Keio University School of Medicine Ophthalmology

kawatetsu@gmail.com0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026